Multiple Myeloma Coverage from Every Angle

Shaji K. Kumar, MD, on Newly Diagnosed Multiple Myeloma: Evolving Treatment Approaches

Posted: Tuesday, December 4, 2018

Shaji K. Kumar, MD, of the Mayo Clinic, describes—and places into context—the phase III findings on daratumumab plus lenalidomide and dexamethasone vs lenalidomide and dexamethasone in people with newly diagnosed multiple myeloma who are ineligible for transplant.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.